

malaria
NO MORE
united kingdom

Zero Malaria: Change the Story



**ANNUAL REPORT
AND ACCOUNTS**

Year ended
31 December 2023

Company number
06648679

Charity number
1126222

CONTENTS



- 3 CHAIR'S LETTER**
- 5 CEO'S LETTER**
- 7 WHY MALARIA?**
- 9 OUR MISSION, VISION, VALUES AND APPROACH**
- 11 ZERO MALARIA: CHANGE THE STORY**
- 15 KENYA: THE POWER OF EVERYONE**
- 17 ZERO MALARIA BRITAIN: FINISH THE JOB**
- 21 DIRECTORS REPORT AND ACCOUNTS**

CHAIR'S LETTER



2023 marked a significant moment within the fight to end malaria. For the first time, the World Health Organization's 2023 World Malaria Report included a chapter on the intersection between climate change and malaria. Changes in temperature, humidity and rainfall are making it more difficult to manage and deliver malaria control programmes. For instance, catastrophic flooding in Pakistan in 2022 led to a five-fold increase in malaria cases in the country.

Despite the challenge climate change poses to the malaria fight, we have seen significant milestones achieved. In a historic development, the World Health Organization recommended a second malaria vaccine - R21, developed by the Jenner Institute at Oxford University. This recommendation paves the way for significant expansion in the global supply of vaccines, combined with the previously approved RTS,S (developed by GSK), increasing the diverse range of tools available to combat malaria.

Yet, we must not get complacent. Malaria remains a formidable threat. In 2022, there were approximately 249 million cases of and 608,000 deaths due to malaria worldwide and almost 90% of malaria deaths occur in children under the age of five, predominantly in sub-Saharan Africa. These staggering numbers illustrate the urgent need for sustained intervention.

To get back on track in the fight against malaria, the use of vaccines will need to be balanced alongside continued investment in efforts to expand access to and optimise the use of existing interventions, like insecticide treated nets, indoor residual spraying and anti-malarial medication. The upcoming replenishments of Gavi, The Vaccine Alliance, and The Global Fund to Fight AIDS, Tuberculosis and Malaria will be of critical importance in ensuring vaccines and lifesaving tools are rolled out at scale.

As ever, I am proud to share the remarkable work Malaria No More UK (MNMUK) has delivered towards ending malaria in our lifetimes. In 2023, amidst financial constraints, political volatility, and climate change, MNMUK seized crucial opportunities to lay the groundwork for future success.

MNMUK's collaborative campaign "Zero Malaria: Change the Story" not only shed light on the



nexus of climate change and malaria but also provided a platform for endemic country voices to resonate globally.

MNMUK continued to highlight British scientific achievements, championing the innovative contributions of British science and advocating for sustained investment in malaria research and development. MNMUK continues to pave the way for critical funding pledges and policy advancements and continues to make the case for the UK government to play its role and 'Finish The Job'.

In Kenya, 2023 has been a critical year in the co-creation and development of an exciting, bold new national and county level campaign which will be launched in early 2024 – calling on the power of everyone to lead change and end malaria for good.

None of this work would be possible without the unwavering dedication of our partners and the tireless efforts of the MNMUK team. I extend my heartfelt gratitude to you all for your continued support and collaboration.

I also wish to express my appreciation to MNMUK's former Board Chair, Baroness Liz Sugg CBE, for her exemplary leadership. As we embark on this journey together, let us remain committed to ending malaria and creating a healthier, malaria-free world for generations to come.

David Reddy
Interim Board Chair

CEO'S LETTER



“As I reflect on 2023, I am filled with gratitude and pride for the dedication and passion demonstrated by our team, partners, and supporters in the fight against malaria.”

Amid constrained overseas development aid (ODA), political instability, and the threat of climate change, 2023 emerged as a pivotal year to lay the groundwork for the successful replenishments of The Global Fund to Fight AIDS, Tuberculosis and Malaria, and Gavi, the Vaccine Alliance, in 2024/25.

In the UK, in anticipation of a General Election in 2024, the team strategically positioned British backed science to drive malaria prioritisation and resource mobilisation. Through “Zero Malaria Britain” we garnered support from MPs and policymakers, securing commitments from the UK government towards malaria research and development. The “Finish the Job,” campaign generated public and cross-party support ahead of the 2024 General Election, ensuring malaria remains a priority amidst competing agendas.

In 2023, the global focus on health and climate change reached new heights, culminating in COP28’s historic Health Day, where over 50 Health Ministers convened, committing US\$1 billion to tackle climate-related health challenges. Through strategic partnerships and innovative campaigns such as “Zero Malaria: Change the Story”, launched at COP28 with MNMUK’s newest young Ambassador, Ellyanne Wanjiku Chlystun and long-time Ambassador David Beckham, we called on leaders to listen to the voices of children affected by malaria and climate change. The team met with future Royal Patron His Majesty The King who reiterated his commitment to the fight to end malaria.

The team continued to support the international campaign to end malaria – particularly through our work with RBM Partnership to End Malaria, as well as collaborating with the UK’s Foreign, Commonwealth and Development Office (FCDO), the African Leaders Malaria Alliance (ALMA), The President’s Malaria Initiative (PMI) and the World Health Organization (WHO). MNMUK rolled out key tools such as the Commonwealth Health Ministers Briefing 2023 to support policy decision-making at the Commonwealth Health Ministers’ meeting.

In Kenya, with support from Fever-Tree, MNMUK, through its leadership within the Zero Malaria Campaign Coalition (ZMCC) led the development, deployment and testing of an innovative communication campaign designed to amplify and accelerate social behaviour change communications in three malaria-endemic counties in Kenya – Kisumu, Kakamega and Kilifi.

The campaign has been co-created with leading malaria partners and with communities and local actors driving the fight against malaria in Kenya. The campaign will be focused on the actions that every person in Kenya can take to contribute to ending malaria – featuring community heroes from pregnant women to Community Health Care workers. This bold and innovative campaign will be launched and rolled out through 2024.

Alongside delivering this groundbreaking work, the team used 2023 to reflect and set out a new five-year strategy, guided by refreshed organisational values. This new strategy will be launched in 2024 and will guide our work through to 2028.

Looking ahead, 2024 will be a crucial year in the fight against malaria. With both Gavi, the Vaccine Alliance (Gavi) and the Global Fund to Fight Aids, Tuberculosis and Malaria (Global Fund) replenishments expected in 2025, the global malaria community will need to build the political will for long term investment in malaria now. As the UK enters a General Election period, UK support for malaria from all political parties will be vital and will lay the groundwork for successful replenishments in 2025. Kenya will see the launch of the Power of EveryONE campaign and a new national malaria strategy, with MNMUK primed to mobilise political leaders to influence globally for Gavi and the Global Fund.

These achievements are made possible through the generous support of our funding partners, including The Gates Foundation, Open Philanthropy, Fever-Tree, GSK, Rentokil Initial and Medicines for Malaria Venture, alongside contributions from our donors and supporters. I extend my gratitude for your unwavering commitment to our shared cause.

Finally, I would like to thank our team and partners, whose relentless efforts continue to drive us closer to our goal of eradicating this preventable and treatable disease. Together, we stand united to reach a world without malaria in our lifetimes.”



**Dr Astrid Bonfield CBE
CEO, Malaria No More UK**



WHY MALARIA?

Malaria is one of the world's oldest and deadliest diseases, crippling health systems, draining economies, perpetuating poverty, and claiming lives – one child dies from malaria every minute.

And yet, malaria is preventable and treatable. We now have the strongest malaria-fighting toolbox that we've ever had and potentially many more game-changing tools on their way.

Already, we have seen significant progress in the fight to end malaria with more than half of the world's countries now malaria free. If we act now, a unique opportunity is within our reach. Ending malaria has the potential to:

- **Save lives and improve health outcomes for those most at risk (pregnant women and young children)**
- **Reduce the global health burden, and healthcare costs regionally, nationally and at household level**
- **Unlock major economic and development gains, with economies seeing productivity boosts as fewer people fall ill or die**

Ending malaria would represent a major victory for humankind – and set the path to the eradication of other deadly diseases.

**Tabinda, 12
Pakistan**



Tabinda Hussain is a 12 year old 6th-grade student. The tranquillity of her village in Pakistan would be disrupted by devastating floods that would leave an indelible mark on the lives of its residents.

“During the floods, a lot of water came. Our houses fell down. Our livestock died. All the people from our village left. Because of the floods, there was a lot of dirty water and due to that, mosquitoes came and then everyone got ill. When I got ill, I had a headache and my eyes used to hurt and they were watery.”

With their Basic Health Unit submerged, accessing medical care seemed impossible. However, a glimmer of hope emerged in the form of Indus Hospital, which had set up medical camps to address the health crisis.

“Then we found out that Indus Hospital has arranged medical camps. So we went there. There was a doctor there. I was tested and found positive for malaria. They gave me medicines, and that helped me recover. People from Indus Hospital also gave us awareness about how to protect ourselves from malaria.”

Tabinda recovered and is now back at school. In the wake of tragedy, Tabinda and her community learned to rebuild not just their homes but also their defences against the invisible threats that lurked in the aftermath of the floods.

With thanks to Indus Hospital and Health Network

“**Because of the floods there was a lot of dirty water and due to that, mosquitoes came and then everyone got ill.**”

OUR MISSION, VISION, VALUES AND APPROACH

Vision A world without malaria in our lifetimes.

Mission Our mission is to catalyse and inspire the global partnerships, leadership and financing to end malaria.

Values

In 2023, MNMUK, with support from Inclusive Village, conducted a participatory review of our organisational values. We are pleased to share our values which shape how we work.

Our integrated campaign approach

At Malaria No More UK, our mission is to end malaria in our lifetimes. To do this, we have a vision to reduce deaths and cases from malaria by 90% by 2030. For this to happen we need innovation to develop new programmes and tools and funding to deliver new and existing malaria programmes and tools. Beyond technical capabilities, we also need the political will to drive and implement change -- at global level, country, and local levels.

Our integrated campaign model combines politically sophisticated advocacy with disruptive creative communication strategies. We believe that when advocacy and creative communications are used together and coordinated to engage target audiences, we can maximise impact. The MNMUK model is applied by deploying the right tools and leveraging a complex combination of resources, partnerships, and powerful voices to create a multiplier effect.



Collective Voice

We believe that through the combined power of many voices, lived experiences and diverse perspectives, we will end malaria for good.



Creativity

We believe in the power of creative ideas. Drawing from diverse skills, experiences and cultures, we foster innovative thinking that will bring us closer to our vision of a malaria free world.

Ambition

We will embody a brave, bold and determined spirit, challenging ourselves and others to aim for greater impact in the malaria fight.



Inclusivity

We are fully committed to the practices and behaviours that promote and uphold principles of equity, diversity and inclusion.


Agility

To be responsive to the needs of our communities and deliver impact in an ever-changing world, we actively listen, learn and adapt.




OUR VALUES

David Beckham
Malaria No More UK
Leadership Council



“To know that a child dies every single minute, it’s quite shocking. When you speak to children about this, they want to be heard. They want to be the voice of change.”



ZERO MALARIA: CHANGE THE STORY


2023 saw the launch of the **Zero Malaria: Change the Story** campaign, a child-centred storytelling campaign highlighting the impact that malaria is having on children around the world and the impact that rising threats, including climate change, are having on efforts to end the disease. Children are most affected by malaria – yet their voices often go unheard. A child dies every minute from this disease, and they bear the brunt of the impact that threats such as climate change and other crises are having on the disease. Zero Malaria: Change the Story places children’s stories from some of the countries most affected by malaria at the heart of the campaign.

Launched at COP28 and laying the foundations for successful replenishments of the Global Fund to Fight AIDS, Tuberculosis and Malaria and Gavi, The vaccine alliance, in subsequent years, the campaign calls on leaders to listen to the voices of children affected by malaria and the impacts of climate change and to make decisions now that will change the story for millions of children around the world.


The first phase of this campaign calls on governments to urgently ensure there is adequate funding to make sure health systems and malaria programmes are resilient in the face of a changing climate and able to rapidly respond to extreme weather events.

Since the campaign was launched at COP28 in Dubai, it has reached over 420m people across 11 countries and has been translated into six languages. We have seen 45 global partners support the campaign.

MNMUK will continue to act as the steward of the “Zero Malaria: Change The Story” campaign, working with partners to deploy future creative communication and advocacy activities under this campaign in 2024 and beyond. Doing so will put the voice of children, those most affected by malaria, at the heart of the campaign and help build a platform to encourage endemic and donor country leaders to heed their call and support further investments in malaria elimination, particularly through the upcoming replenishments of Gavi and the Global Fund.



Zero Malaria: Change the Story



“**Every one of us children in the Ghetto Kids lives with malaria. We all know what it feels like to get malaria and how scary it is. And now climate change is making malaria even harder to fight.**”

King, just 14 years old, is one of the lead dancers from the iconic Ugandan dance group The Ghetto Kids. However, his life is at constant risk from malaria. King is determined to use his voice and his incredible talent for dance to change the story for children across the world.

“Malaria is my worst enemy. Malaria killed my best friend, Keli, three years ago. He was nine. I think about him all the time.”


On top of losing his beloved friend, King has struggled with his own health due to malaria. “I’ve had malaria six times. The last time I had it, I started feeling pain in both my legs. The X-ray showed that I had a crack in my knee – a dislocation. Because of that I was not able to perform in the final of Britain’s Got Talent.”

Malaria mostly affects children, diminishing their potential, keeping them out of school and holding back their education. “Malaria affects my education and my future,” says King. “When I’m sick, I can’t walk. I can’t dance. I can’t go to school and focus.”

It doesn’t have to be this way. King says: “Nothing is impossible. It is possible to find a vaccine for malaria. It is already happening. If we had it sooner maybe my best friend would still be alive. We can end malaria forever. I know the experts and the scientists are very hard working now, but they have to keep going. I know they can do it. I love them so much.”

King is proud to be a Zero Malaria ambassador and is determined to be part of ending this disease for good.

King, 14
Uganda



“**Malaria is my worst enemy. Malaria killed my best friend three years ago. He was nine. I think about him all the time.**”



KENYA: THE POWER OF EVERYONE

As part of Kenya's goal to reach Zero Malaria by 2030, Malaria No More UK is working in our role as Secretariat to the Zero Malaria Campaign Coalition (ZMCC) to deliver a new nationwide campaign designed to unite the public (particularly youth) and political leaders in the belief and action that will make a Zero Malaria Kenya possible.

The campaign aims to raise malaria as a priority for leaders and decision makers in Kenya, while a pilot project will see the campaign adapted for audiences in three malaria endemic counties of Kilifi, Kisumu and Kakamega and targeting promotion of behaviour change.

We have been working with partners in these target counties to help increase the impact of existing behaviour change and malaria control programmes. Extensive insight gathering during 2023 has helped build an understanding of the key behaviour change required within each county to drive deeper impact in communities.

By working closely with a partnership of creative experts, government, NGOs, media, youth and health workers, through the ZMCC, MNMUK have developed a creative campaign led by community insights and tested through focus group discussions amongst key audiences in Nairobi and in the three target counties – Kilifi, Kakamega and Kisumu.

The resulting national Zero Malaria Starts With Me Campaign "The Power of EveryONE" and its tailored adaptations across three endemic counties will be launched by Kenya's Zero Malaria Campaign Coalition in early 2024.



World Malaria Day 2023 saw the Kenya Malaria Youth Corps embark on a cross-county roadshow featuring the Zero Malaria Starts With Me 'Fight the Bite' activation developed in partnership with Dentsu Kenya.

The Youth Corps visited communities across the endemic counties, sharing awareness and crucial information.

Fight the Bite World Malaria Day county roadshow



ZERO MALARIA BRITAIN AND FINISH THE JOB

MNMUK has strategically positioned itself to influence the international development agenda of the largest political parties in anticipation for the 2024 UK general election.

Throughout 2023, with a General Election anticipated for 2024, our “Zero Malaria Britain” communications and advocacy built momentum towards strong future replenishments for the Global Fund and Gavi, alongside making the case for multi-year government investment in Product Development Partnerships (PDPs). We highlighted the groundbreaking contributions of British-backed malaria science, the role the UK government can play as part of a ‘global team,’ of nations and partnered with influential figures like photographer Rankin. Our message was amplified through various media, national and regional outlets, parliamentary engagements, and political moments. This resulted in a multi-year funding opportunity for PDPs as well as the Foreign Secretary announcing a £12 million investment into how to successfully deploy vaccines alongside other tools.

In anticipation of a UK general election in 2024, we responded to the shifting political landscape by launching “Finish the Job”, a campaign that was designed to demonstrate public support for ending malaria to political audiences in key UK constituencies.

We used media opportunities to emphasise the importance of British science, UK health security, and saving children’s lives to advocate for UK investment in the full suite of malaria medicine and preventative tools to combat malaria effectively.

Despite global challenges, the UK maintains a pivotal role in the fight to end malaria. MNMUK will continue its campaign efforts, highlighting British-backed science and showcasing the impact ending malaria has on global health security and economic growth.



“The British life science sector has been key to a lot of the developments we’ve had so far in malaria... It’s important for the public to know how big of a problem malaria is.”



To highlight the importance of British science in the fight against malaria, we shone the spotlight on eight incredible scientists working to end this disease.

We joined forces with the iconic British portrait photographer Rankin to capture these rising stars, and the story featured in the Telegraph ahead of World Malaria Day.

Malaria scientists in the spotlight with Rankin



Freddy Sarathchandra
Laboratory scientist
and PhD candidate

Transitioning from mechanical engineering to the life sciences, Freddy Sarathchandra, a PhD student at the London School of Hygiene and Tropical Medicine, is breaking new ground by studying mosquito sounds to develop advanced surveillance tools.

Originally trained as a mechanical engineer, Freddy is applying his technical expertise to public health, aiming to identify mosquitoes through their unique sounds. "My garage got turned into a lab and a workshop, and I designed all the weird, wacky machines. I thought, I need to figure out what that sound of a mosquito is all about."

A key focus of his research is the importance of collaboration and input from those directly affected by malaria. Freddy emphasises the need for easier communication channels between researchers in the UK and communities impacted by the disease. "One of the barriers that is really apparent to me is that it's very important when working on a topic like malaria to have input from all parties involved and for me, I am very keen to listen to the voices of people that are affected by malaria."

The global scale of malaria, which causes over 600,000 deaths each year, drives Freddy's passion for developing new surveillance and control tools. He also has a personal connection to the impact of mosquito-borne diseases. "I'm originally from Sri Lanka, which actually successfully was declared malaria-free recently. But I've seen firsthand when I go to Sri Lanka the burden on health that mosquito-borne diseases have. It feels very personal to me."

"I think it is definitely possible to see a zero malaria world within our lifetime."

“In one year there was about 624,000 deaths just from malaria alone, and this statistic just seems insane to me.”

DIRECTORS REPORT AND ACCOUNTS



KEY INFORMATION

Leadership Council

David Beckham OBE
Sir Andy Murray OBE
Eliud Kipchoge

Global Patrons

Adebola Williams
The Rt Hon Baroness Hayman GBE
Dame Heather Rabbatts CBE
Andy Ransom

Our major funders during the year

The Gates Foundation
Fever-Tree Mixers
Open Philanthropy
Medicines for Malaria Venture
GSK
Rentokil Initial

Partners donating resource, talent and time

Dentsu
Global Malaria Creative Collective
Rankin
Zero Malaria Campaign Coalition members



The Trustees are pleased to present their report together with the audited financial statements of the charity for the year to 31 December 2023. The accounts have been prepared in accordance with the accounting policies set out in note 1 to the accounts and comply with the Charity's Memorandum and Articles of Association, the Companies Act 2006 and the Statement of Recommended Practice 'Accounting and Reporting by Charities' (revised 2015).

Structure, governance and management governing document

Malaria No More United Kingdom is a charitable company limited by guarantee, incorporated on 16 July 2008 and registered as a charity on 8 October 2008. The company is governed by its Memorandum and Articles of Association.

Directors

The directors of the charitable company are its Trustees for the purpose of charity law, and the members of the company limited by guarantee. Throughout this report, they are collectively referred to as the Trustees.

The following individuals served as Trustees during the year:

Andrew Cook (resigned on 23 April 2023)

Prof Azra Ghani (resigned 14 May 2023)

Sophie O'Connor (Treasurer, resigned 19 June 2023)

Linda Yueh (resigned 16 January 2023)

Baroness Elizabeth Grace Sugg (resigned 17 November 2023)

Sarah Douglas

Norman Mbazima

Feyi Olubodun

Dr David Reddy

Eva Thorne

Geoffrey Love (appointed 28 September 2023)

Stewart Cox (appointed 28 September 2023)

All Trustees served for the full year unless otherwise stated above.

No Trustees had any beneficial interest in the charity, and no Trustee is paid remuneration by the charity.

The Board of Trustees is responsible for the charity's strategic direction, policy and governance.

The implementation of the strategy, once agreed, and the day-to-day running and management of the charity's activities are delegated to the secretariat, led by the Chief Executive Officer.

Risk management

The Trustees regularly review the charity's risks and are satisfied that relevant systems are in place to mitigate their exposure to major risks. The charity maintains a risk register that is updated quarterly. The top three Risks are:

- Adverse publicity results from the actions of active stakeholders, such as staff, management, a Trustee, ambassadors, partners, or a funder.
- The reserve level is inadequate, which means the charity cannot meet its obligations if other financial risks occur. It also means the charity does not have enough funds to take advantage of opportunities that could help beneficiaries or pay contractual costs to stakeholders.
- GDPR & Data Retention risk is caused by sharing or using data inappropriately, leading to data breach, ICO investigation, and possible fine. Keeping data beyond the need for purpose and/or keeping out-of-date information or personal information beyond limitations - covers all MNMUK storage and systems.

All risks have mitigation strategies and monitoring actions identified and are reviewed and updated regularly.

MNMUK maintains a risk register that the leadership team updates and reviews regularly. The Audit and Risk Committee is mandated to review the risk register and provide feedback and guidance to the Trustees. The Committee met five times in 2023.

MNMUK has a Crisis Management Team led by the Chief Executive Officer, which meets at least once every quarter.

Public benefit

The Trustees confirm that they have complied with their duty under Section 17 (5) of the Charities Act 2011 to have due regard to the Charity Commission's general guidance on public benefit.

Senior executive remuneration

Salaries for permanent staff across all functions have been set in line with market rate indicators and internal parity. Any salary adjustments made in the year aligned with the organisations policy on salary banding.

The charity publishes the salaries of its key management personnel in its annual report. The number of staff paid over £60,000 is also published in accordance with the charity accounting requirements.

Structure, governance and management

Malaria No More UK is a registered charity and a company limited by guarantee without share capital and is governed by its memorandum and articles of association. The group includes a wholly owned subsidiary company, Malaria No More Trading, through which its 'cause marketing' activities are carried out.

The charity is governed by the Board of Trustees. The Board operates a quarterly meeting cycle, with an Audit and Risk Committee meeting before the main Board meeting. The Board, with the Executive Directors, reviews progress against the organisation's strategic aims, governance and structure, and consideration of the changing external environment. The retail operations were governed separately by the Malaria No More Trading director, Dr Astrid Bonfield.

In 2022, MNMUK registered the Kenya legal entity as a branch company of MNMUK.

Fundraising practices

As part of MNMUK's commitment to best practice, the charity adheres to the fundraising Codes of Practice set by the Fundraising Regulator and the Institute of Fundraising.

MNMUK is committed to ensuring that fundraising is open, respectful, and transparent to the public. The charity has several clearly documented policies and procedures, including a complaints policy, which enables any concerns from the public regarding MNMUK's fundraising practices to be heard and addressed in a timely manner. During the year, no complaints were received from the general public. There have also been no instances of non-compliance with the fundraising code of practice requirements.

The charity has a transparent way of working with vulnerable individuals. This fundraising policy clearly states all steps that should be followed to protect vulnerable people when offering support to the charity, ensuring that they have the relevant capacity to enable them to make the decision to donate.

Equity, Diversity and Inclusion

MNMUK's Equality Diversity and Inclusion Strategy guides the organisation to ensure our works does not produce, reproduce or sustain the inequalities, exclusions and oppressions that we seek to address in the fight to end malaria. Beyond this, our ambition through our EDI strategy is to embed a social justice approach to the work that we do and the malaria fight, and centre EDI principles in how we are led and how we advocate and influence both internally and externally. In 2023, the organisations focus was on reviewing and refreshing our values through a consultative process facilitated by Inclusive Village. These values (outlined above) guide our work both internally and externally.

Financial review

During 2023, MNMUK continued to receive support from longstanding partner the Gates Foundation. The second payment of the three-year grant (2022-2025) - "Unlocking the Path to Eradication"- was received in March 2023. This contribution is central to supporting MNMUK's work to help catalyse the political commitment, financing, and collective action needed to reach international malaria reduction targets and establish a pathway to achieving malaria elimination.


As MNMUK continued to deliver Africa-focused advocacy and communications, including the Zero Malaria Campaign Coalition in Kenya and the continued development and delivery of Zero Malaria brand communications, restricted funding support was deployed and received from various donors, including long-term supporters Fever-Tree and Rentokil Initial (the continued deployment of funds donated in 2022).

The second instalment of the £2.6m Open Philanthropy two-year grant was received in October 2023. The funding will support advocacy and campaigns for donor and Commonwealth malaria funding.

Further designated funding was received from Medicines for Malaria Venture and pharmaceutical company GSK, to support MNMUK's UK and global advocacy and communications work.


As hosts of the All- Party Parliamentary Group (APPG) secretariat for Malaria and NTDs, MNMUK received £45,000 in restricted funding from APPG supporters.

Review of 2023 income, and comparison with 2022



MNMUK receives only limited income in the form of donations and fundraising from members of the public, meaning that the support of those individuals and community groups who do contribute to the charity is even more gratefully received. In 2023, almost £210,257 was received through public fundraising activities, which included £2,698 received through the HMRC Gift Aid scheme and £125,752 in Legacy income.

Review of 2023 expenditure, and comparison with 2022



Expenditure rose by 8% (£351,074) from £4,429,086 to £4,780,161. Of this total, 75% was spent on direct charitable activities (2022: 76%). The expenditure on direct project costs fell by £244,495 in 2022 to £1,808,792 in 2023 following the end of the Kigali Summit for Malaria and NTDs. The net decrease in resources for the year was £44,459 (2022: decrease of £348,809).

At the end of the period, the charity's Balance Sheet remains strong, with net assets of £1,962,430 compared to £2,006,889 in 2022. Restricted funds amounted to £1,030,445 compared to £860,785 in 2022. The total cash in hand available to the Charity decreased by £2,435,260 from £4,722,664 to £2,287,403 in 2023. This decrease is mainly due to a reduction in grant income received in advance in 2023.

MNMUK benefited significantly from a wide range of pro bono support provided to the charity. This includes but is not limited to, gifts in kind received from celebrities, including David Beckham, global influencers, Yemi Alade, and highly valuable media support from the Dentsu Group.

While the value of these contributions extends to many millions of pounds, only a portion of this is reflected in the accounts as Gifts in Kind (£319,000 in 2022; £675,108 in 2022) based on the price that the charity would otherwise be prepared to pay in the open market.

Reserves

The Trustees' policy, updated in November 2022, is to maintain two reserves, together shown on the balance sheet as unrestricted funds: one, equivalent to the value of 4 months core operating costs (The Resilience Reserve), and two, reserves allocated to specific future projects to be delivered within 24 months (The Designated Reserves).

The resilience reserve based on planned fixed expenditure for 2024 is £1,113,076, while the designated reserve is £556,538. At the end of 2023, the unrestricted reserves amounted to £916,538, which is the year's Resilience Reserve; we have no designated reserves to carry forward to 2024.

A new fundraising strategy aimed at diversifying income and building our reserves was introduced in January 2024.

Responsibilities of trustees in relation to the financial statements

The Trustees (also the directors of Malaria No More UK for the purposes of company law) are responsible for preparing the Report of the Trustees and the financial statements per applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Company law requires the Trustees to prepare financial statements for each financial year which give a true and fair view of the charitable company's state of affairs and the incoming resources and application of resources, including the income and expenditure, of the charitable company for that period. In preparing those financial statements, the Trustees are required to:

- Select suitable accounting policies and then apply them consistently;
- Observe the methods and principles in the Charity SORP;
- Make judgements and estimates that are reasonable and prudent;
- Prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charitable company will continue in business.

The Trustees are responsible for keeping proper accounting records which disclose with reasonable accuracy at any time the financial position of the charitable company and to enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the charitable company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities. In so far as the Trustees are aware:

- There is no relevant audit information of which the charitable company's auditors are unaware; and
- The Trustees have taken all steps that they ought to have taken to make themselves aware of any relevant audit information and to establish that the auditors are aware of that information.

This report was approved by the Board of Trustees on 17th July 2024 and signed on its behalf by:

Stewart Forster Cox, Treasurer

David Reddy, Interim Board Chair

Independent auditors' report

Opinion

We have audited the financial statements of Malaria No More UK (the 'parent charitable company') and its subsidiaries (the 'group') for the year ended 31 December 2023 which comprise the consolidated statement of financial activities, the group and parent charitable company balance sheets, the consolidated statement of cash flows and the notes to the financial statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including FRS 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting Practice).

In our opinion, the financial statements:

- Give a true and fair view of the state of the group's and of the parent charitable company's affairs as at 31 December 2023 and of the group's incoming resources and application of resources, including its income and expenditure, for the year then ended
- Have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice
- Have been prepared in accordance with the requirements of the Companies Act 2006 and the Charities Act 2011

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the group financial statements section of our report. We are independent of the group and parent charitable company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions related to going concern

In auditing the financial statements, we have concluded that the Trustees' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on Malaria No More UK's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the Trustees with respect to going concern are described in the relevant sections of this report.

Other information

The other information comprises the information included in the Trustees' annual report other than the group financial statements and our auditor's report thereon. The Trustees are responsible for the other information contained within the annual report. Our opinion on the group financial statements does not cover the other information, and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon. Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the group financial statements, or our knowledge obtained in the course of the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the group financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

Opinions on other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of the audit:

- The information given in the Trustees' annual report for the financial year for which the financial statements are prepared is consistent with the financial statements
- The Trustees' annual report has been prepared in accordance with applicable legal requirements

Matters on which we are required to report by exception

In the light of the knowledge and understanding of the group and the parent charitable company and their environment obtained in the course of the audit, we have not identified material misstatements in the Trustees' annual report.

We have nothing to report in respect of the following matters in relation to which the Companies Act 2006 and Charities Act 2011 requires us to report to you if, in our opinion:

- Adequate accounting records have not been kept by the parent charitable company, or returns adequate for our audit have not been received from branches not visited by us; or
- The parent charitable company financial statements are not in agreement with the accounting records and returns; or
- Certain disclosures of Trustees' remuneration specified by law are not made; or
- We have not received all the information and explanations we require for our audit; or
- The directors were not entitled to prepare the financial statements in accordance with the small companies regime and take advantage of the small companies' exemptions in preparing the Trustees' annual report and from the requirement to prepare a strategic report.

Responsibility of Trustees

As explained more fully in the statement of Trustees' responsibilities set out in the Trustees' annual report, the Trustees (who are also the directors of the parent charitable company for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the Trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the Trustees are responsible for assessing the group's and the parent charitable company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Trustees either intend to liquidate the group or the parent charitable company or to cease operations, or have no realistic alternative but to do so.

Auditors' responsibilities for the audit of financial statements

We have been appointed auditor under the Companies Act 2006 and section 151 of the Charities Act 2011 and report in accordance with those Acts.

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud are set out below.

Capability of the audit in detecting irregularities

In identifying and assessing risks of material misstatement in respect of irregularities, including fraud and non-compliance with laws and regulations, our procedures included the following:

- We enquired of management, which included obtaining and reviewing supporting documentation, concerning the group's policies and procedures relating to:
- Identifying, evaluating, and complying with laws and regulations and whether they were aware of any instances of non-compliance;
- Detecting and responding to the risks of fraud and whether they have knowledge of any actual, suspected, or alleged fraud;
- The internal controls established to mitigate risks related to fraud or non-compliance with laws and regulations.
- We inspected the minutes of meetings of those charged with governance.

- We obtained an understanding of the legal and regulatory framework that the group operates in, focusing on those laws and regulations that had a material effect on the financial statements or that had a fundamental effect on the operations of the group from our professional and sector experience.
- We communicated applicable laws and regulations throughout the audit team and remained alert to any indications of non-compliance throughout the audit.
- We reviewed any reports made to regulators.
- We reviewed the financial statement disclosures and tested these to supporting documentation to assess compliance with applicable laws and regulations.
- We performed analytical procedures to identify any unusual or unexpected relationships that may indicate risks of material misstatement due to fraud.
- In addressing the risk of fraud through management override of controls, we tested the appropriateness of journal entries and other adjustments, assessed whether the judgements made in making accounting estimates are indicative of a potential bias and tested significant transactions that are unusual or those outside the normal course of business.

Because of the inherent limitations of an audit, there is a risk that we will not detect all irregularities, including those leading to a material misstatement in the financial statements or non-compliance with regulation. This risk increases the more that compliance with a law or regulation is removed from the events and transactions reflected in the financial statements, as we will be less likely to become aware of instances of non-compliance. The risk is also greater regarding irregularities occurring due to fraud rather than error, as fraud involves intentional concealment, forgery, collusion, omission, or misrepresentation.

A further description of our responsibilities is available on the Financial Reporting Council's website at: www.frc.org.uk/auditorsresponsibilities. This description forms part of our auditor's report.

Use of our report

This report is made solely to the charitable company's members as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006 and section 144 of the Charities Act 2011 and regulations made under section 154 of that Act. Our audit work has been undertaken so that we might state to the charitable company's members those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charitable company and the charitable company's members as a body, for our audit work, for this report, or for the opinions we have formed.

Jonathan Orchard (Senior statutory auditor)

for and on behalf of Sayer Vincent LLP, Statutory Auditor
110 Golden Lane, LONDON, EC1Y 0TG

Consolidated statement of financial activities (incorporating an income and expenditure account)

For the year ended 31 December 2023

	Note	2023		2022	
		Unrestricted £	Restricted £	Unrestricted £	Restricted £
Income from:					
Donations and legacies	2	529,257	143,768	715,135	454,894
Charitable activities	3		3,887,441		2,795,957
Other trading activities	4	100,000	-	100,071	-
Investments		15,981	40,000	10,863	-
Other		44	-	788	-
Total income		645,282	4,071,209	826,857	3,250,851
Expenditure on:					
Raising funds	5	216,154		324,621	
Charitable activities		662,458	3,901,549	833,370	3,271,096
Total expenditure		878,612	3,901,549	1,157,991	3,271,096
Net income / (expenditure) before net gains / (losses) on investments		(233,330)	169,660	(331,134)	(20,245)
Net gains / (losses) on investments		19,212	-	2,570	-
Net income for the year	6	(214,119)	169,660	(328,564)	(20,245)
Net movement in funds		(214,119)	169,660	(328,564)	(20,245)
Reconciliation of funds:					
Total funds brought forward		1,146,104	860,785	1,474,668	881,030
Total funds carried forward		931,986	1,030,445	1,146,104	860,785

All of the above results are derived from continuing activities. There were no other recognised gains or losses other than those stated above. Movements in funds are disclosed in Note 18a to the financial statements.

Balance sheets

As at 31 December 2023

Note	The group		The charity	
	2023 £	2022 £	2023 £	2022 £
Fixed assets:				
Tangible assets	9	15,447	12,805	12,805
Investments	17	1,544,457	502,571	502,571
		1,559,904	515,376	515,376
Current assets:				
Debtors	12	253,225	273,113	253,323
Cash at bank and in hand		2,287,405	4,722,664	4,658,765
		2,540,630	4,995,777	4,912,088
Liabilities:				
Creditors: Deferred income	14	(1,754,546)	(3,263,915)	(3,263,915)
Creditors: amounts falling due within one year	13	(383,558)	(240,350)	(229,720)
		(2,138,104)	(3,504,265)	(3,493,635)
Net current assets		402,527	1,491,512	1,418,453
Total assets less current liabilities		1,962,430	2,006,888	1,933,829
Funds:	18a			
Unrestricted income funds		931,986	865,287	
Resilience reserve		931,986	946,104	873,045
Designated reserve		-	200,000	200,000
Total unrestricted funds		931,986	1,146,104	1,073,045
Restricted income funds		1,030,445	860,785	860,785
Total funds		1,962,431	2,006,889	1,933,830

Approved by the Board of Trustees on 17th July 2024 and signed on its behalf by:

David Reddy, Interim Board Chair

Consolidated statement of cash flows

For the year ended 31 December 2023

Note	2023		2022	
	£	£	£	£
Cash flows from operating activities				
Net income for the reporting period (as per the statement of financial activities)	(44,459)		(348,809)	
Depreciation charges	13,713		10,674	
(Gains)/losses on investments	(19,212)		(2,570)	
Dividends, interest and rent from investments	(55,981)		(10,863)	
Decrease / (increase) in debtors	19,888		193,205	
Increase in creditors	143,208		17,929	
Increase/(decrease) in deferred income	(1,509,369)		1,752,306	
Net cash provided by operating activities	(1,452,211)		1,611,872	
Cash flows from investing activities:				
Dividends, interest and rents from investments	55,981		10,863	
Purchase of fixed assets	(16,355)		(14,232)	
Proceeds from sale of investments	1,000,000		-	
Purchase of investments	(2,022,675)		(500,000)	
Net cash used in investing activities	(983,049)		(503,369)	
Change in cash and cash equivalents in the year	(2,435,260)		1,108,503	
Cash and cash equivalents at the beginning of the year	4,722,664		3,614,161	
Cash and cash equivalents at the end of the year	2,287,405		4,722,664	

Notes to the financial statements

For the year ended 31 December 2023

1 Accounting policies

a) Statutory information

Malaria No More UK is a charitable company limited by guarantee. It is registered in England and Wales and incorporated in the United Kingdom.

The registered office address is Millbank Tower, 21-24 Millbank, London, SW1P 4QP.

b) Basis of preparation

The financial statements have been prepared in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) - (Charities SORP FRS 102), The Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Companies Act 2006.

Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy or note.

In applying the financial reporting framework, the trustees have made a number of subjective judgements, for example in respect of significant accounting estimates. Estimates and judgements are continually evaluated and are based on historical experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances. The nature of the estimation means the actual outcomes could differ from those estimates. Any significant estimates and judgements affecting these financial statements are detailed within the relevant accounting policy below.

c) Public benefit entity

The charity meets the definition of a public benefit entity under FRS 102.

d) Going concern

The trustees are aware that some long standing funding streams will be ending in the near future. To mitigate that, the charity is focussed on a strategy of income diversification. Planning has also been undertaken to identify financially viable models based on different future funding scenarios.

The trustees are confident that a future sustainable model can be identified and that there are no material uncertainties about the charity's ability to continue as a going concern.

The trustees do not consider that there are any sources of estimation uncertainty at the reporting date that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next reporting period.

e) Income

All incoming resources are included in the statement of financial activities when the charity is entitled to the income and the amount can be quantified with reasonable accuracy. The following specific policies are applied to particular categories of income.

- Donations and legacies are received by way of grants, donations and gifts and are included in full in the statement of financial activities when receivable. Grants receivable are recognised when the charity becomes unconditionally entitled to the grant. A gift aid donation from the trading subsidiary to the charity is accrued when the gift aid payment is payable under a legal obligation. Measurement is at the fair value receivable, which is the transaction value.
- Gifts in kind represent donated services and facilities for use by the Charity, and are recognised when receivable. Gifts in kind are measured and valued at an estimate of the price the Charity would otherwise have paid on the open market. Where donated facilities and services have been consumed by year end an equivalent amount is recognised as an expense under the appropriate heading in the statement of financial activities.
- The value of services provided by volunteers has not been included as income in these accounts.
- Investment income is included when receivable.

f) Fund accounting

- Unrestricted funds are available for use at the discretion of the trustees in furtherance of the general objectives of the charity.
- Restricted funds are subject to specific conditions imposed by the donor as to how they may be used. The purposes and uses of the restricted funds are set out in the notes to the accounts.

1 Accounting policies (continued)

g) Expenditure and irrecoverable VAT

Expenditure is recognised on an accruals basis as a liability is incurred, and includes any VAT which cannot be fully recovered.

- Expenditure on charitable activities comprises expenditure related to the direct furtherance of the charity's objectives. Grants payable are included under charitable expenditure when a contract is signed with the grantee. Where costs cannot be directly attributed, they have been allocated to activities on a basis consistent with the use of resources.
- Support costs relate to those functions that assist the work of the charity but do not directly undertake charitable activities. Support costs include back office costs, finance, personnel and governance costs. These costs have been allocated to fund raising and specific areas of charitable activity on a basis consistent with the use of resources.
- The value of services provided by volunteers has not been included as expenditure in these accounts.

h) Operating leases

Rental costs are charged on a straight line basis over the term of the lease.

Notes to the financial statements

For the year ended 31 December 2023

i) **Tangible fixed assets**

Tangible fixed assets costing over £500 (including any incidental expenses of acquisition) are capitalized. Depreciation is provided at rates calculated to write off the cost on a straight line basis over their expected useful economic life. The rate of depreciation is 33.33% per annum for all assets.

j) **Foreign currency**

Transactions in foreign currencies are initially recorded in the entity's functional currency, which is pound sterling, by applying the spot exchange rate on the date of the transaction. Monetary assets and liabilities denominated in foreign currencies are translated at the rate of exchange on the balance sheet date. All differences are taken to the statement of financial activities.

k) **Debtors**

Trade and other debtors are recognised at the settlement amount due after any trade discount offered. Prepayments are valued at the amount prepaid net of any trade discounts due.

l) **Cash at bank and in hand**

Cash at bank and cash in hand includes cash and short term highly liquid investments with a short maturity of three months or less from the date of acquisition or opening of the deposit or similar account.

m) **Creditors and provisions**

Creditors and provisions are recognised where the charity has a present obligation resulting from a past event that will probably result in the transfer of funds to a third party and the amount due to settle the obligation can be measured or estimated reliably. Creditors and provisions are normally recognised at their settlement amount after allowing for any trade discounts due.

n) **Deferred income**

Income is deferred by the charity only if there is a donor-imposed condition or restraint preventing the recognition of restricted income in the SoFA. This is in line with the charity's income recognition policy.

o) **Financial instruments**

The charity only has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value.

2 **Income from donations and legacies**

	Unrestricted £	Restricted £	2023 Total £	Unrestricted £	Restricted £	2022 Total £
Donations	210,257	143,768	354,025	40,027	454,894	494,921
Donated services	319,000	-	319,000	675,108	-	675,108
	529,257	143,768	673,025	715,135	454,894	1,170,029

Donated services represent pro bono time of numerous celebrities, legal and catering services and communications and PR

3 **Income from charitable activities**

	Unrestricted £	Restricted £	2023 Total £	Unrestricted £	Restricted £	2022 Total £
Grants	-	3,887,441	3,887,441	-	2,795,957	2,795,957

4 **Income from other trading activities**

	Unrestricted £	Restricted £	2023 Total £	Unrestricted £	Restricted £	2022 Total £
Cause related marketing	100,000	-	100,000	100,071	-	100,071

Notes to the financial statements

For the year ended 31 December 2023

5a Analysis of expenditure (current year)

	Charitable activities					2023	Total	2022	Total
	Raising funds £	UK Campaign and Activities £	Global Campaign and Activities £	Governance £	Support costs £	£	£	£	£
Staff costs (Note 7)	78,423	960,195	793,516	16,021	304,397	2,152,552		1,826,834	
Direct project costs	-	507,529	1,301,262	-	-	1,808,792		2,053,287	
HR, recruitment and training	-	-	-	13,648	122,833	136,482		136,359	
Legal and professional	-	-	-	-	8,286	8,286		10,378	
Premises	-	-	-	-	211,547	211,547		95,050	
Office running costs	-	-	-	-	144,943	144,943		108,686	
Audit	-	-	-	13,800	-	13,800		12,900	
Consultancy costs	-	-	-	-	70,297	70,297		24,319	
Strategic Development costs	-	-	-	-	86,301	86,301		373	
Other costs	-	-	-	21,211	99,498	120,709		87,075	
Fundraising costs	26,453	-	-	-	-	26,453		73,826	
	104,876	1,467,724	2,094,778	64,680	1,048,103	4,780,162		4,429,086	
Support costs	104,810	431,811	511,482		(1,048,103)				
Governance costs	6,468	26,648	31,564	(64,680)					
Total expenditure 2023	216,154	1,926,183	2,637,825	-	-	4,780,162		4,429,086	
Total expenditure 2022	-	-	-	-	-	-		-	

Included in direct project costs are grants payable of £54,552.59 (2022: £158,299) to one partner, WACI Health.

For the year ended 31 December 2023

5b Analysis of expenditure (prior year)

	Charitable activities					2022	Total £
	Raising funds £	UK Campaign and Activities £	African Campaign and Activities £	Governance £	Support costs £		
Staff costs (Note 7)	169,636	792,449	528,300	16,822	319,626	1,826,834	
Direct project costs	-	847,275	1,206,012	-	-	2,053,287	
HR, recruitment and training	-	-	-	13,636	122,723	136,359	
Legal and professional	-	-	-	-	10,378	10,378	
Premises	-	-	-	-	95,050	95,050	
Office running costs	-	-	-	-	108,686	108,686	
Audit	-	-	-	12,900	-	12,900	
Other costs	-	-	-	4,234	107,533	111,767	
Fundraising costs	73,826	-	-	-	-	73,826	
	243,462	1,639,724	1,734,311	47,592	763,996	4,429,086	
Support costs	76,400	371,289	316,307	-	(763,996)		
Governance costs	4,759	23,129	19,704	(47,592)	-		
Total expenditure 2022	324,621	2,034,142	2,070,322	-	-	4,429,086	

For the year ended 31 December 2023

6 Net income for the year

This is stated after charging / (crediting):

	2023 £	2022 £
Depreciation	13,713	10,675
Operating lease rentals:		
Property	195,945	79,489
Auditor's remuneration (excluding VAT):		
Audit	11,500	10,750

7 Analysis of staff costs, trustee remuneration and expenses, and the cost of key management personnel

Staff costs were as follows:

	2023 £	2022 £
Salaries and wages	1,789,970	1,499,880
Pension	170,224	152,070
Social security costs	192,358	174,884
	2,152,552	1,826,834

	2023 No.	2022 No.
--	-------------	-------------

The average number of full-time equivalent employees during the period was

30 25

The average number of staff (headcount basis) during the period was

33 29

The number of staff whose emoluments were in excess of £60,000 during the year were as follows:

	2023 No.	2022 No.
£60,001 - £70,000	4	5
£70,001 - £80,000	4	1
£80,001 - £90,000	3	2
£90,001 - £100,000	-	1
£100,001 - £110,000	-	-
£110,001 - £120,000	1	-

The total employee benefits (including pension contributions and employer's national insurance) of the key management personnel were £527,374.11 (2022: £535,390.44).

The charity did not pay to its trustees any remuneration during the year (2022: £nil) or any reimbursed trustee expenses (2023: £105).

8 Taxation

The charity is exempt from tax on income and gains falling within section 505 of the Taxes Act 1988 or section 252 of the Taxation of Chargeable Gains Act 1992 to the extent that these are applied to its charitable objects.

For the year ended 31 December 2023

9 Tangible fixed assets - charity and group

	Computer equipment £	Total £
Cost		
At the start of the year	58,073	58,073
Additions in year	16,355	16,355
Disposals in year	-	-
At the end of the year	<u>74,428</u>	<u>74,428</u>
Depreciation		
At the start of the year	45,268	45,268
Charge for the year	13,713	13,713
Eliminated on disposal	-	-
At the end of the year	<u>58,981</u>	<u>58,981</u>
Net book value		
At the end of the year	<u>15,447</u>	<u>15,447</u>
At the start of the year	<u>12,805</u>	<u>12,805</u>

All of the above assets are used for charitable purposes.

10 Subsidiary undertaking

The Consolidated Statement of Financial Activities includes the results of the charity and its wholly owned subsidiary Malaria No More UK Trading Limited, which conducts trading and merchandising activities on behalf of the charity. The company pays all of its profits to the charity by a gift aid donation. Malaria No More UK Trading Limited is registered under company number 07621448 and its registered office is at Millbank Tower, 21-24 Millbank, London, SW1P 4QP.

A summary of the results of the subsidiary is shown below:

	2023 £	2022 £
Turnover	100,000	100,071
Cost of sales & administrative expenses	(33,302)	(27,012)
Gross profit	66,699	73,059
Retained earnings		
Total retained earnings brought forward	73,059	401,219
Profit/loss for the financial year	66,699	73,059
Distribution under Gift Aid to parent charity	(73,059)	(401,219)
Total retained earnings carried forward	66,699	73,059
The aggregate of the assets, liabilities and reserves was:		
Assets	132,688	93,899
Liabilities	(65,989)	(20,841)
Reserves	66,699	73,059

11 Parent charity

The parent charity's gross income and the results for the year are disclosed as follows:

	2023 £	2022 £
Gross income	4,669,004	4,006,586
Result for the year	(111,733)	(421,867)

For the year ended 31 December 2023

12 Debtors

	The group		The charity	
	2023	2022	2023	2022
	£	£	£	£
Trade debtors	125,353	120,999	125,353	90,999
Inter group debtor			65,414	10,210
Rent deposit	32,177	5,183	32,177	5,183
Accrued income	-	124,365	-	124,365
Other debtors	95,695	22,566	95,695	22,566
	<u>253,225</u>	<u>273,113</u>	<u>318,639</u>	<u>253,323</u>

13 Creditors: amounts falling due within one year

	The group		The charity	
	2023	2022	2023	2022
	£	£	£	£
Trade creditors	241,452	57,925	240,762	57,295
Inter group creditor				
Deferred income	1,754,546	3,263,915	1,754,546	3,263,915
Sundry creditors and accruals	142,106	182,425	142,221	172,425
	<u>2,138,104</u>	<u>3,504,264</u>	<u>2,137,529</u>	<u>3,493,634</u>

14 Deferred income

Deferred income comprises BMGF and OP income received during the 2023 financial year which was not available for spending in the year. The deferred balance is expected to be utilised over the 2024 financial year in line with the grant agreement.

	The group		The charity	
	2023	2022	2023	2022
	£	£	£	£
Balance at the beginning of the year	3,263,915	1,511,608	3,263,915	1,511,608
Amount released to income in the year	(4,036,590)	(2,824,520)	(4,036,590)	(2,824,520)
Deferred income received in the year	2,527,221	4,576,826	2,527,221	4,576,826
Balance at the end of the year	<u>1,754,546</u>	<u>3,263,915</u>	<u>1,754,546</u>	<u>3,263,915</u>

15 Pension scheme

The charity operates an auto-enrolment pension scheme with The Peoples Pension. All staff are eligible, and the charity pays 10% employer's contribution in addition to any personal contribution made by the staff themselves. The charity also allows staff who have "opted out" of the auto-enrolment scheme to nominate a personal pension plan to receive their pension contribution.

Pension costs stated in note 9 and charged in the Statement of Financial Activities represent the total contributions payable by the charity in the year.

16a Analysis of group net assets between funds (current year)

	General unrestricted £	Restricted funds £	Total funds £
Tangible fixed assets	15,447	-	15,447
Investments	1,060,240	484,217	1,544,457
Current assets	239,856	2,300,774	2,540,630
Current liabilities	(383,558)	(1,754,546)	(2,138,104)
Net assets at 31 December 2023	<u>931,985</u>	<u>1,030,445</u>	<u>1,962,430</u>

For the year ended 31 December 2023

16b Analysis of group net assets between funds (prior year)

	General unrestricted £	Restricted funds £	Total funds £
Tangible fixed assets	12,805	-	12,805
Investments	502,570	-	502,570
Current assets	871,077	4,124,700	4,995,777
Current liabilities	(240,350)	(3,263,915)	(3,504,265)
Net assets at 31 December 2022	1,146,102	860,785	2,006,887

17 Listed investments

	The group		The charity	
	2023 £	2022 £	2023 £	2022 £
Fair value at the start of the year	502,570	-	502,570	-
Additions at cost	2,022,675	500,000	2,022,675	500,000
Disposal proceeds	(1,000,000)	-	(1,000,000)	-
Net gain / (loss) on change in fair value	19,212	2,570	19,212	2,570
Fair value at the end of the year	1,544,457	502,570	1,544,457	502,570

Investments comprise:

	The group		The charity	
	2023 £	2022 £	2023 £	2022 £
UK Common investment funds	1,544,061	502,570	1,544,061	502,570
Cash	396	-	396	-
Total	1,544,457	502,570	1,544,457	502,570

18a Movements in funds (current year)

	At 1 January 2023 £	Income & gains £	Expenditure & losses £	Transfers £	At 31 December 2023 £
Restricted funds:					
The Gates Foundation	413,527	2,525,441	(2,470,710)	-	468,258
All-party parliamentary group	76,983	45,000	(48,891)	-	73,093
GlaxoSmithKline plc	-	85,000	(85,000)	-	-
Medicines for Malaria Venture	-	58,768	(58,768)	-	-
Open Philanthropy	-	1,357,000	(935,777)	-	421,223
RES Africa	293,087	-	(225,215)	-	67,871
RES Summit	77,188	-	(77,188)	-	-
Total restricted funds	860,785	4,071,209	(3,901,549)	-	1,030,445
Unrestricted funds:					
General funds	1,146,104	664,494	(878,612)	-	931,986
Designated reserve	200,000	-	-	(200,000)	-
Total funds	2,206,889	4,735,703	(4,780,161)	(200,000)	1,962,431

The narrative explaining the purpose of each fund is given at the foot of the note below.

For the year ended 31 December 2023

18b Movements in funds (prior year)

	At 1 January 2022 £	Income & gains £	Expenditure & losses £	Transfers £	At 31 December 2022 £
Restricted funds:					
The Gates Foundation	590,000	2,234,520	(2,410,992)	-	413,527
All-Party Parliamentary Group	68,037	47,500	(38,554)	-	76,983
GlaxoSmithKline plc	70,000	70,000	(140,000)	-	-
Rentokil Initial plc	44,000	4,276	(48,276)	-	-
Medicines for Malaria Venture	30,000	76,063	(106,063)	-	-
RBM Partnership to End Malaria	78,993	57,373	(136,366)	-	-
New Venture Fund	-	202,879	(202,879)	-	-
RES Africa	-	380,618	(87,532)	-	293,087
RES Summit	-	177,623	(100,435)	-	77,188
Total restricted funds	881,030	3,250,851	(3,271,096)	-	860,785
Unrestricted funds:					
Resilience reserve	1,474,668	629,427	(1,157,991)	-	946,104
Designated reserve	-	200,000	-	-	200,000
Total unrestricted funds	1,474,668	829,427	(1,157,991)	-	1,146,104
Total funds	2,355,698	4,080,278	(4,429,087)	-	2,006,889

Purposes of restricted funds

The Gates Foundation

MNM UK receives funding from the The Gates Foundation directly from the Foundation. This funding covers a wide range of organisational activities including supporting the charity's campaigns and advocacy work in the UK and beyond.

Open Philanthropy

MNM UK received a two-year grant from Open Philanthropy to support advocacy and campaigns for donor and Commonwealth malaria funding.

All-party parliamentary group

MNM UK hosts the All-party parliamentary group on Malaria and NTDs and receives funding from The Leprosy Mission, on behalf of the UK Coalition Against NTDs, Medicines for Malaria Venture, Path MVI, Sightsavers - Uniting to Combat NTDs, and Drugs for Neglected Diseases initiative (DNDi). This funding supports the charity's advocacy work in the UK and beyond.

GlaxoSmithKline plc

GlaxoSmithKline plc (GSK) funded MNMUK's activities in the UK including supporting the charity's campaigns and advocacy work.

Medicines for Malaria Venture

Medicines for Malaria Venture (MMV) donated funds to support MNMUK's UK and global advocacy and communications work.

RES Africa

MNMUK received funding from Motsepe Foundation and long-term supporters Fever-Tree to support the organisation's continued delivery of Africa focused advocacy and communications work.

RBM Partnership to End Malaria, NVF, RES Summit

MNMUK received funding from RBM Partnership to End Malaria, New Venture Fund and several sector partners to support the delivery of the Kigali Malaria and NTD Summit and associated communications work in 2022.

19 Operating lease commitments payable as a lessee

The charity moved its head office in February 2023 and this has been leased until 31 January 2025. The cost of this is shown below:

	2023 £	2022 £
Less than one year	165,802	126,654
Between two and five years	13,817	149,682
Total	179,618	276,336

malaria
NO MORE
united kingdom

